Hepatitis B Virus News and Research

RSS

New saliva-based test found to accurately detect the presence of SARS-CoV-2 antibodies

A new saliva-based test developed by a team at Johns Hopkins Bloomberg School of Public Health has been found to accurately detect the presence of antibodies to SARS-CoV-2, the virus that causes COVID-19, from small samples of saliva, according to a study led by Bloomberg School researchers.

15 Nov 2020

New prediction model may make it easier to find which infants will develop NAS

A new Vanderbilt-designed prediction model may make it easier to determine which infants will go on to develop neonatal abstinence syndrome (NAS), a drug withdrawal syndrome in newborns that occurs after exposure to opioids during pregnancy.

12 Nov 2020

COVID-19 treatments for people with early infection should be prioritized

COVID-19 treatments for people with early infection are needed urgently, according to a JAMA Viewpoint article by National Institute of Allergy and Infectious Diseases (NIAID) Director Anthony S. Fauci, M.D., and colleagues.

11 Nov 2020

SARS-CoV-2 viral antigens found in non-pulmonary tissues in recovering patients

A team of researchers in Singapore, led by Dr. Joe Yeong, and Prof. Tony Kiat Hon Lim, have reported the presence of residual SARS-CoV-2 ribonucleic acid (RNA) – the virus' genetic material – in stool samples and gastrointestinal tissues from patients recovering from the coronavirus disease 2019 (COVID-19).

8 Nov 2020

Remdesivir metabolite GS-441524 inhibits SARS CoV-2 in mouse model, finds study

This new study titled, "Remdesivir Metabolite GS-441524 Efficiently Inhibits SARS-CoV-2 Infection in Mouse Model," was released online as a preprint on the bioRxiv* server, prior to undergoing the peer-review process.

2 Nov 2020

Dietary restriction effective in reducing the odds of developing liver cancer from fatty liver

Liver cancer from too much fat accumulation in the liver has been increasing in many countries including Japan.

29 Oct 2020

Study may pave way for more effective treatment for Hepatitis C

Virologists at Institut national de la recherche scientifique (INRS) have identified a critical role played by a cellular protein in the progression of Hepatitis C virus infection, paving the way for more effective treatment.

22 Oct 2020

Researchers receive €2.35 million to examine disease pathways of viruses

Two University College Dublin (UCD) researchers and SiriusXT, a UCD spin-out company, have been awarded a total of €2.35 million in funding for a disruptive photonics technology project, through Horizon 2020, the EU's research and innovation programme, to examine the disease pathways of viruses.

9 Oct 2020

Case report of arthritis in a COVID-19 patient

The current paper published in the The Lancet Rheumatology discusses arthritis in a 58-year-old white woman with COVID-19 of less than severe intensity.

7 Oct 2020

Sofosbuvir combined with other antivirals is more effective against COVID-19, shows study

Columbia Engineering researchers report that Sofosbuvir-terminated RNA is more resistant to the proofreader of SARS-CoV-2, the virus that causes COVID-19, than Remdesivir-terminated RNA.

7 Oct 2020

Discovery of high affinity binders for SARS-CoV-2 spike protein

An exciting, 'tour-de-force' paper by researchers from the Massachusetts Institute of Technology describes de novo discovery of high-affinity peptide binders for SARS-CoV-2 spike glycoprotein, which opens the door for the development of rapid viral identification or conjugates for virus-directed delivery of therapeutics.

30 Sep 2020

Parkinson's disease diagnosed after SARS-CoV-2

As the COVID-19 pandemic continues to spread, new and unusual chronic sequelae of the disease are cropping up in many medical practices. Now, a new case paper published in The Lancet in September 2020 describes a case of new-onset Parkinson's disease following infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

22 Sep 2020

New drug candidate suppresses SARS-CoV-2 replication

Researchers at Stanford University and Utah State University have developed a novel inhibitor of the coronavirus main protease (Mpro) that effectively suppresses the viral replication of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

17 Sep 2020

Potential sea animal reservoirs for coronaviruses?

The COVID-19 pandemic has focused, yet again, intense research interest on coronaviruses, due to the high toll the novel coronavirus SARS-CoV-2 has taken on human life, health, economic well-being, and social activity. A recent paper published on the server Preprints in September 2020 reviews what is known about this viral infection in water life.

13 Sep 2020

New method offers hope to patients in critical need of kidney transplant

Kidneys from deceased donors with hepatitis C virus (HCV) infection can be safely transplanted into noninfected recipients when a regimen of direct-acting antiviral therapies is initiated as early as two days after the transplant, according to a study from Massachusetts General Hospital (MGH).

2 Sep 2020

14 existing drugs identified as SARS-CoV-2 main protease inhibitors

Now, a new study published on the preprint server bioRxiv in August 2020 reports on the identification of 14 compounds that can inhibit the key viral enzyme called the Main Protease (MPro) at micromolar concentrations.

1 Sep 2020

BM32 vaccine against grass pollen allergy could be potential treatment for hepatitis B infection

Chronic hepatitis B infections represent a global health problem that could hitherto only be treated by chemotherapy.

26 Aug 2020

Whey protein from human breastmilk inhibits SARS-CoV-2 infection

Many scientists have reported the effects of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection on pregnancy and the virus has been detected in breastmilk. Now a new study published on the preprint server bioRxiv* in August 2020 shows that whey protein in human breastmilk efficiently prevents infection with SARS-CoV-2 as well as post-entry viral replication.

20 Aug 2020

CUNY School of Medicine and TechnoVax announce COVID-19 vaccine breakthrough

The CUNY School of Medicine at The City College of New York and TechnoVax, Inc., a biotechnology developer of novel vaccines, announce a breakthrough in their collaborative effort to develop a vaccine for COVID-19.

19 Aug 2020

De novo designed SARS-CoV-2 nanoparticle vaccine

In light of the continuing threat to public health, social functioning, and economic activity posed by the COVID-19 pandemic, scientists are working urgently to bring out a vaccine that is both safe and effective, and capable of mass production. A new paper published on the preprint server bioRxiv* in August 2020 shows that such a vaccine may be produced by using arrays of one severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) protein on a nanoparticle platform.

14 Aug 2020